ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Universitetsbiblioteket
  • Artikler, rapporter og annet (UB)
  • View Item
  •   Home
  • Universitetsbiblioteket
  • Artikler, rapporter og annet (UB)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review

Permanent link
https://hdl.handle.net/10037/36712
DOI
https://doi.org/10.1080/14740338.2024.2396396
Thumbnail
View/Open
article.pdf (439.0Kb)
Accepted manuscript version (PDF)
Date
2024-09-23
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Solmi, Marco; Miola, Alessandro; Capone, Federico; Pallottino, Simone; Højlund, Mikkel; Firth, Joseph; Siskind, Dan; Holt, Richard IG; Corbeil, Olivier; Cortese, Samuele; Dragioti, Elena; Rietz, Ebba Du; Nielsen, Rene Ernst; Nordentoft, Merete; Fusar-Poli, Paolo; Hartman, Catharina A; Høye, Anne; Koyanagi, Ai; Larsson, Henrik; Lehto, Kelli; Lindgren, Peter; Manchia, Mirko; Skonieczna-Żydecka, Karolina; Stubbs, Brendon; Vancampfort, Davy; Vieta, Eduard; Taipale, Heidi; Correll, Cristoph U.
Abstract
Introduction - People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.

Areas covered - We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.

Expert opinion - To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications’ and patient’s weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.

Publisher
Taylor & Francis
Citation
Solmi, Miola, Capone, Pallottino, Højlund, Firth, Siskind, Holt, Corbeil, Cortese, Dragioti, Rietz, Nielsen, Nordentoft, Fusar-Poli, Hartman, Høye, Koyanagi, Larsson, Lehto, Lindgren, Manchia, Skonieczna-Żydecka, Stubbs, Vancampfort, Vieta, Taipale, Correll. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review. Expert Opinion on Drug Safety. 2024
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (UB) [3245]
Copyright 2024 The Author(s)

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)